The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.
Giuseppe Procopio
Consultant or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Pfizer
Honoraria - Astellas Pharma; Bayer; GlaxoSmithKline; Pfizer
Elena Verzoni
Honoraria - Pfizer
Sergio Bracarda
No relevant relationships to disclose
Sergio Ricci
No relevant relationships to disclose
Laura Ridolfi
No relevant relationships to disclose
Cosimo Sacco
No relevant relationships to disclose
Rosalba Miceli
No relevant relationships to disclose
Camillo Porta
No relevant relationships to disclose
Marco Bregni
No relevant relationships to disclose
Emilio Bajetta
No relevant relationships to disclose